Aveo raises another $100M, as tivozanib goes head-to-head with Nexavar in RCC
16 June 2011
Nancy Faigen
Please Login to read the full article.
16 June 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Aveo licences preclinical RON-targeted antibodies to J&J, for $15 million up front
- Pfizer's Torisel fails in Phase III second-line kidney cancer trial
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- AVEO's unconvincing Phase II ficlatuzumab data point to need for further studies
FEATURES
Other Informa Features
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
